scholarly journals Baseline Meningococcal Carriage in Burkina Faso before the Introduction of a Meningococcal Serogroup A Conjugate Vaccine

2011 ◽  
Vol 18 (3) ◽  
pp. 435-443 ◽  
Author(s):  
Paul A. Kristiansen ◽  
Fabien Diomandé ◽  
Stanley C. Wei ◽  
Rasmata Ouédraogo ◽  
Lassana Sangaré ◽  
...  
Keyword(s):  
Burkina Faso ◽  
Conjugate Vaccine ◽  
Herd Immunity ◽  
Isolation And Identification ◽  
Carriage Rate ◽  
Cross Sectional ◽  
Rural Districts ◽  
Strain Characterization ◽  
The Impact ◽  
Carriage Prevalence

ABSTRACTThe serogroup A meningococcal conjugate vaccine MenAfriVac has the potential to confer herd immunity by reducing carriage prevalence of epidemic strains. To better understand this phenomenon, we initiated a meningococcal carriage study to determine the baseline carriage rate and serogroup distribution before vaccine introduction in the 1- to 29-year old population in Burkina Faso, the group chosen for the first introduction of the vaccine. A multiple cross-sectional carriage study was conducted in one urban and two rural districts in Burkina Faso in 2009. Every 3 months, oropharyngeal samples were collected from >5,000 randomly selected individuals within a 4-week period. Isolation and identification of the meningococci from 20,326 samples were performed by national laboratories in Burkina Faso. Confirmation and further strain characterization, including genogrouping, multilocus sequence typing, andporA-fetAsequencing, were performed in Norway. The overall carriage prevalence for meningococci was 3.98%; the highest prevalence was among the 15- to 19-year-olds for males and among the 10- to 14-year-olds for females. Serogroup Y dominated (2.28%), followed by serogroups X (0.44%), A (0.39%), and W135 (0.34%). Carriage prevalence was the highest in the rural districts and in the dry season, but serogroup distribution also varied by district. A total of 29 sequence types (STs) and 51porA-fetAcombinations were identified. The dominant clone was serogroup Y, ST-4375, P1.5-1,2-2/F5-8, belonging to the ST-23 complex (47%). All serogroup A isolates were ST-2859 of the ST-5 complex with P1.20,9/F3-1. This study forms a solid basis for evaluating the impact of MenAfriVac introduction on serogroup A carriage.

scholarly journals Prevalence of SARS-CoV-2 Infection at the University of Barcelona during the Third COVID-19 Pandemic Wave in Spain

2021 ◽  
Vol 18 (12) ◽  
pp. 6526
Author(s):  
Sebastián Videla ◽  
Aurema Otero ◽  
Sara Martí ◽  
M. Ángeles Domínguez ◽  
Nuria Fabrellas ◽  
...  
Keyword(s):  
Ad Hoc ◽  
Venous Blood ◽  
Herd Immunity ◽  
Cross Sectional Study ◽  
Rt Pcr ◽  
Igg Antibody ◽  
Cross Sectional ◽  
Total Prevalence ◽  
The University ◽  
The Impact

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic started in December 2019 and still is a major global health challenge. Lockdown measures and social distancing sparked a global shift towards online learning, which deeply impacted universities’ daily life, and the University of Barcelona (UB) was not an exception. Accordingly, we aimed to determine the impact of the SARS-CoV-2 pandemic at the UB. To that end, we performed a cross-sectional study on a sample of 2784 UB members (n = 52,529). Participants answered a brief, ad hoc, online epidemiological questionnaire and provided a nasal swab for reverse transcription polymerase chain reaction (RT-PCR) SARS-CoV-2 analysis and a venous blood sample for SARS-CoV-2 IgG antibody assay. Total prevalence of SARS-CoV-2 infection (positive RT-PCR or positive IgG) was 14.9% (95%CI 13.3 to 17.0%). Forty-four participants (1.6%, 95%CI: 1.2–2.1%) were positive for SARS-CoV-2 RT-PCR. IgG against SARS-CoV-2 was observed in 12.8% (95%CI: 11.6–14.1%) of participants. Overall, while waiting for population vaccination and/or increased herd immunity, we should concentrate on identifying and isolating new cases and their contacts.

scholarly journals IMPACT OF MULTIPLEX PCR IN REDUCING THE RISK OF RESIDUAL TRANSFUSION-TRANSMITTED HUMAN IMMUNODEFICIENCY AND HEPATITIS B AND C VIRUSES IN BURKINA FASO

2018 ◽  
Vol 10 (1) ◽  
pp. e2018041 ◽  
Author(s):  
Arzouma Paul YOODA ◽  
Serge Theophile SOUBEIGA ◽  
Kompingnin Yacouba NEBIE ◽  
Birama DIARRA ◽  
Salam SAWADOGO ◽  
...  
Keyword(s):  
Blood Transfusion ◽  
Hepatitis B ◽  
Burkina Faso ◽  
Multiplex Pcr ◽  
Blood Donation ◽  
Cross Sectional Study ◽  
Residual Risk ◽  
Serological Tests ◽  
Cross Sectional ◽  
The Impact

Background and ObjectiveThe improved performance of serological tests has significantly reduced the risk of human immunodeficiency and hepatitis B and C viruses transmission by blood transfusion, but there is a persistence of residual risk. The objective of this study was to evaluate the impact of multiplex PCR in reducing the risk of residual transmission of these viruses in seronegative blood donors in Burkina Faso.MethodsThis cross-sectional study was conducted from March to September 2017. The serological tests were performed on sera using ARCHITECTSR i1000 (Abbot diagnosis, USA). Detection of viral nucleic acids was performed by multiplex PCR on mini-pools of seronegative plasma for HBV, HCV and HIV using SaCycler-96 Real Time PCR v.7.3 (Sacace Biotechnologies). Multiplex PCR-positive samples from these mini-pools were then individually tested by the same method.Results A total of 989 donors aged 17 to 65 were included in the present study. "Repeat donors" accounted for 44.79% (443/989). Seroprevalences for HIV, HBV, and HCV were 2.53% (25/989), 7.28% (72/989) and 2.73% (27/989), respectively. Of the 14 co-infections detected, HBV/HCV was the most common with 0.71% (7/989) of cases. Of 808 donations tested by multiplex PCR, 4.70% (38/808) were positive for HBV while no donation was positive for HIV or HCV.Conclusion: Our study showed a high residual risk of HBV transmission through blood transfusion. Due to the high prevalence of blood-borne infections in Burkina Faso, we recommend the addition of multiplex PCR to serologic tests for optimal blood donation screening.

scholarly journals B Part of It School Leaver protocol: an observational repeat cross-sectional study to assess the impact of a meningococcal serogroup B (4CMenB) vaccine programme on carriage ofNeisseria meningitidis

BMJ Open ◽  
2019 ◽  
Vol 9 (5) ◽  
pp. e027233 ◽  
Author(s):  
Helen S Marshall ◽  
Mark McMillan ◽  
Ann Koehler ◽  
Andrew Lawrence ◽  
Jenny MacLennan ◽  
...  
Keyword(s):  
Controlled Trial ◽  
Age Groups ◽  
Case Fatality ◽  
Cluster Randomised Controlled Trial ◽  
Cross Sectional Study ◽  
Sectional Study ◽  
School Students ◽  
Cross Sectional ◽  
The Impact ◽  
Carriage Prevalence

IntroductionInvasive meningococcal disease is uncommon but associated with a high-case fatality rate. Carriage prevalence of the causative bacteria,Neisseria meningitidis, is high in adolescents. A large (n=34 500) cluster randomised controlled trial (RCT) to assess the impact of a meningococcal B (MenB) vaccine on meningococcal carriage was implemented in the state of South Australia (SA) for year 10, 11 and 12 senior school students in 2017–2018. This study will assess the impact of MenB vaccine (4CMenB) on carriage prevalence in school leavers in SA, 1 and 2 years after implementation of the cluster RCT in adolescents. Measuring the impact of population programmes on carriage can assist in informing future meningococcal immunisation programmes such as targeted age groups and use of catch-up campaigns.Methods and analysisThis repeat cross-sectional study will assess carriage prevalence in 2018 and 2019. All school leavers who attended year 12 in any school in SA in 2018 or 2019 will be invited to participate in this study. An oropharyngeal swab will be taken from each participating student and a risk factor questionnaire completed by the student following informed consent. Students will attend clinics at SA universities, technical colleges, and metropolitan, rural and remote government council clinics. Confirmed vaccination history will allow a comparison in carriage prevalence between vaccinated and unvaccinated school leavers. A sample size of 4096 students per year will provide 80% power to detect a 20% difference in carriage prevalence of disease-causing meningococci (defined as genogroup A, B, C, W, X or Y) between years.Ethics and disseminationThe study was approved by the Women’s and Children’s Health Network Human Research Ethics Committee. Results will be published in international peer review journals and presented at national and international conferences.Trial registration numberNCT03419533; Pre-results

HIV infection among pregnant women in Burkina Faso: a nationwide serosurvey

1997 ◽  
Vol 8 (10) ◽  
pp. 646-651 ◽  
Author(s):  
Lassina Sangare ◽  
Nicolas Meda ◽  
Salif Lankoande ◽  
Eddy Van Dyck ◽  
Michel Cartoux ◽  
...  
Keyword(s):  
Hiv Infection ◽  
Burkina Faso ◽  
Pregnant Women ◽  
Screening Method ◽  
Syphilis Infection ◽  
Cross Sectional ◽  
Hiv Surveillance ◽  
The North ◽  
The Impact ◽  
Syphilis Serology

To determine the prevalence of HIV infection among pregnant women in Burkina Faso and to identify factors associated with HIV infection in this population, we performed in 4 antenatal clinics in 4 urban centres located in the centre, the north, the east and the south-west of the country cross-sectional serological surveys between 7 October 1994 and 7 February 1995 using unlinked anonymous HIV screening method. In the towns included in the study more than 94% of pregnant women attend at least 2 antenatal consultations. In each centre all pregnant women attending an antenatal consultation during a 2-week period were invited to take part in a study to measure the prevalence of syphilis. Women with positive syphilis serology were offered treatment free of charge. A total of 1294 pregnant women were recruited into the study. There were no refusals. Thirty-two women (2.5%) had positive syphilis serology. The overall seroprevalence of HIV infection was 8% (95% confidence interval [CI]: 6.6-9.6). There was no evidence that the prevalence of syphilis or HIV infection varied between the 4 towns ( P =0.12 and 0.52 respectively). In logistic regression analyses only the presence of syphilis infection was associated with risk of HIV (odds ratio=3.4; 95% CI: 1.4-7.9). The prevalence of syphilis among pregnant women in Burkina Faso is relatively low compared with that of HIV infection. These results suggest that HIV epidemic in Burkina Faso is important and that there is an urgent need to intensify HIVprevention activities. The need for HIV surveillance in this sentinel population is urgent to follow the course of the epidemic and to measure the impact of interventions. One of the consequences of the high prevalence of HIV infection among pregnant women which requires greater attention in Burkina Faso is the increasing number of children who will be infected with HIV by vertical transmission.

scholarly journals Evaluation of the Impact of Meningococcal Serogroup A Conjugate Vaccine Introduction on Second-Year-of-Life Vaccination Coverage in Burkina Faso

2019 ◽  
Vol 220 (Supplement_4) ◽  
pp. S233-S243 ◽  
Author(s):  
Robert L Zoma ◽  
Jenny A Walldorf ◽  
Felix Tarbangdo ◽  
Jaymin C Patel ◽  
Alpha Oumar Diallo ◽  
...  
Keyword(s):  
Burkina Faso ◽  
Conjugate Vaccine ◽  
Age Groups ◽  
Immunization Coverage ◽  
Vaccine Introduction ◽  
Second Year Of Life ◽  
Second Year ◽  
Household Cluster ◽  
Vaccine Availability ◽  
The Impact

Abstract Background After successful meningococcal serogroup A conjugate vaccine (MACV) campaigns since 2010, Burkina Faso introduced MACV in March 2017 into the routine Expanded Programme for Immunization schedule at age 15–18 months, concomitantly with second-dose measles-containing vaccine (MCV2). We examined MCV2 coverage in pre- and post-MACV introduction cohorts to describe observed changes regionally and nationally. Methods A nationwide household cluster survey of children 18–41 months of age was conducted 1 year after MACV introduction. Coverage was assessed by verification of vaccination cards or recall. Two age groups were included to compare MCV2 coverage pre-MACV introduction (30–41 months) versus post-MACV introduction (18–26 months). Results In total, 15 925 households were surveyed; 7796 children were enrolled, including 3684 30–41 months of age and 3091 18–26 months of age. Vaccination documentation was observed for 86% of children. The MACV routine coverage was 58% (95% confidence interval [CI], 56%–61%) with variation by region (41%–76%). The MCV2 coverage was 62% (95% CI, 59%–65%) pre-MACV introduction and 67% (95% CI, 64%–69%) post-MACV introduction, an increase of 4.5% (95% CI, 1.3%–7.7%). Among children who received routine MACV and MCV2, 93% (95% CI, 91%–94%) received both at the same visit. Lack of caregiver awareness about the 15- to 18-month visit and vaccine unavailability were common reported barriers to vaccination. Conclusions A small yet significant increase in national MCV2 coverage was observed 1 year post-MACV introduction. The MACV/MCV2 coadministration was common. Findings will help inform strategies to strengthen second-year-of-life immunization coverage, including to address the communication and vaccine availability barriers identified.

‘B Part of It’ School Leaver study: a repeat cross-sectional study to assess the impact of increasing coverage with meningococcal B (4CMenB) vaccine on carriage of Neisseria meningitidis

2021 ◽  
Author(s):  
Mark McMillan ◽  
Ann P Koehler ◽  
Andrew Lawrence ◽  
Thomas R Sullivan ◽  
Jana Bednarz ◽  
...  
Keyword(s):  
South Australia ◽  
Final Analysis ◽  
Invasive Disease ◽  
Cross Sectional Study ◽  
Cross Sectional ◽  
Oropharyngeal Swab ◽  
Risk Of Disease ◽  
4Cmenb Vaccine ◽  
The Impact ◽  
Carriage Prevalence

Abstract Background Recombinant protein-based vaccines targeting serogroup B meningococci protect against invasive disease, but impacts on carriage are uncertain. This study assessed carriage prevalence of disease-associated meningococci from 2018-2020, as the proportion of vaccinated adolescents increased following introduction of a school-based 4CMenB immunisation program. Methods Eligible participants who completed high school (age 17-25) in South Australia in the previous year had an oropharyngeal swab taken and completed a risk factor questionnaire. Disease-associated meningococci (genogroups A, B, C, W, X, Y) were detected by meningococcal and genogroup-specific polymerase chain reaction. Results The final analysis included 4104 participants in 2018, 2690 in 2019, and 1338 in 2020. The proportion vaccinated with 4CMenB increased from 43% in 2018, to 78% in 2019, and 76% in 2020. Carriage prevalence of disease-associated meningococci in 2018 was 225/4104 (5.5%). There was little difference between the carriage prevalence in 2019 (134/2690, 5.0%, adjusted odds ratio [aOR] 0.82, 95% CI 0.64-1.05) and 2020 (68/1338, 5.1% aOR 0.82, 95% CI 0.57-1.17) compared to 2018. Conclusions Increased 4CMenB uptake in adolescents was not associated with a decline in carriage of disease-associated meningococci. 4CMenB immunisation programs should focus on direct (individual) protection for groups at greatest risk of disease.

scholarly journals Molecular insights into meningococcal carriage isolates from Burkina Faso 7 years after introduction of a serogroup A meningococcal conjugate vaccine

2020 ◽  
Vol 6 (12) ◽  
Author(s):  
Nadav Topaz ◽  
Paul Arne Kristiansen ◽  
Susanna Schmink ◽  
Malika Congo-Ouédraogo ◽  
Dinanibè Kambiré ◽  
...  
Keyword(s):  
Burkina Faso ◽  
Conjugate Vaccine ◽  
Type Species ◽  
Vaccination Campaign ◽  
Mass Vaccination ◽  
Cross Sectional ◽  
Content Type ◽  
Link Type ◽  
Mass Vaccination Campaign ◽  
Sequence Types

In 2010, Burkina Faso completed the first nationwide mass-vaccination campaign of a meningococcal A conjugate vaccine, drastically reducing the incidence of disease caused by serogroup A meningococci. Since then, other strains, such as those belonging to serogroups W, X and C, have continued to cause outbreaks within the region. A carriage study was conducted in 2016 and 2017 in the country to characterize the meningococcal strains circulating among healthy individuals following the mass-vaccination campaign. Four cross-sectional carriage evaluation rounds were conducted in two districts of Burkina Faso, Kaya and Ouahigouya. Oropharyngeal swabs were collected for the detection of Neisseria meningitidis by culture. Confirmed N. meningitidis isolates underwent whole-genome sequencing for molecular characterization. Among 13 758 participants, 1035 (7.5 %) N . meningitidis isolates were recovered. Most isolates (934/1035; 90.2 %) were non-groupable and primarily belonged to clonal complex (CC) 192 (822/934; 88 %). Groupable isolates (101/1035; 9.8 %) primarily belonged to CCs associated with recent outbreaks in the region, such as CC11 (serogroup W) and CC10217 (serogroup C); carried serogroup A isolates were not detected. Phylogenetic analysis revealed several CC11 strains circulating within the country, several of which were closely related to invasive isolates. Three sequence types (STs) were identified among eleven CC10217 carriage isolates, two of which have caused recent outbreaks in the region (ST-10217 and ST-12446). Our results show the importance of carriage studies to track the outbreak-associated strains circulating within the population in order to inform future vaccination strategies and molecular surveillance programmes.

scholarly journals Meningococcal carriage 7 years after introduction of a serogroup A meningococcal conjugate vaccine in Burkina Faso: results from four cross-sectional carriage surveys

2020 ◽  
Vol 20 (12) ◽  
pp. 1418-1425 ◽  
Author(s):  
Sarah Mbaeyi ◽  
Emmanuel Sampo ◽  
Kambiré Dinanibè ◽  
Issaka Yaméogo ◽  
Malika Congo-Ouédraogo ◽  
...  
Keyword(s):  
Burkina Faso ◽  
Conjugate Vaccine ◽  
Cross Sectional

scholarly journals Impact of 13-Valent Pneumococcal Conjugate Vaccine on Pneumococcal Meningitis, Burkina Faso, 2016–2017

2019 ◽  
Vol 220 (Supplement_4) ◽  
pp. S253-S262 ◽  
Author(s):  
Heidi M Soeters ◽  
Dinanibè Kambiré ◽  
Guetawendé Sawadogo ◽  
Rasmata Ouédraogo-Traoré ◽  
Brice Bicaba ◽  
...  
Keyword(s):  
Burkina Faso ◽  
Conjugate Vaccine ◽  
Pneumococcal Conjugate Vaccine ◽  
Pneumococcal Meningitis ◽  
Age Groups ◽  
Clinical Information ◽  
Latex Agglutination ◽  
Childhood Immunization ◽  
Serotype 1 ◽  
The Impact

Abstract Background In 2013, Burkina Faso introduced 13-valent pneumococcal conjugate vaccine (PCV13) into the routine childhood immunization program, to be administered to children at 8, 12, and 16 weeks of age. We evaluated the impact of PCV13 on pneumococcal meningitis. Methods Using nationwide surveillance, we gathered demographic/clinical information and cerebrospinal fluid (CSF) results for meningitis cases. Pneumococcal cases were confirmed by culture, polymerase chain reaction (PCR), or latex agglutination; strains were serotyped using PCR. We compared annual incidence (cases per 100 000) 4 years after PCV13’s introduction (2017) to average pre-PCV13 incidence (2011–2013). We adjusted incidence for age and proportion of cases with CSF tested at national laboratories. Results In 2017, pneumococcal meningitis incidence was 2.7 overall and 10.5 (<1 year), 3.8 (1–4 years), 3.5 (5–14 years), and 1.4 (≥15 years) by age group. Compared to 2011–2013, PCV13-serotype incidence was significantly lower among all age groups, with the greatest decline among children aged <1 year (77%; 95% confidence interval [CI], 65%–84%). Among all ages, the drop in incidence was larger for PCV13 serotypes excluding serotype 1 (79%; 95% CI, 72%–84%) than for serotype 1 (52%; 95% CI, 44%–59%); incidence of non-PCV13 serotypes also declined (53%; 95% CI, 37%–65%). In 2017, 45% of serotyped cases among all ages were serotype 1 and 12% were other PCV13 serotypes. Conclusions In Burkina Faso, meningitis caused by PCV13 serotypes continues to decrease, especially among young children. However, the concurrent decline in non-PCV13 serotypes and short pre-PCV13 observation period complicate evaluation of PCV13’s impact. Efforts to improve control of serotype 1, such as switching from a 3 + 0 schedule to a 2 + 1 schedule, may improve overall control of pneumococcal meningitis in this setting.

Sign in / Sign up

Export Citation Format

Share Document